CLOTRIMAZOLE

US Approved OTC

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H17ClN2
Molecular Weight	344.837
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=CC=C1C(N2C=CN=C2)(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=VNFPBHJOKIVQEB-UHFFFAOYSA-N

InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018052Orig1s032lbl.pdf

Clotrimazole is an anti-fungal medicine indicated for the treatment of vaginal yeast infections and tinea. It can be used either in combination with other drugs (betamethasone dipropionate) or alone, in form of topical or vaginal cream. The drug exerts its action by inhibiting lanosterol demethylase thereby affecting the growth of fungi.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 51 28 Target ID: CHEMBL1780 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Inhibitor 8504		19.7 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Vaginal yeast infections 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018052Orig1s032lbl.pdf	Curative	Approved 8583	GYNE-LOTRIMIN Approved Use To treat vaginal yeast infections. Launch Date 1976
Tinea pedis 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Curative	Approved 8583	LOTRISONE Approved Use LOTRISONE cream contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. Launch Date 1984
Tinea cruris 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Curative	Approved 8583	LOTRISONE Approved Use LOTRISONE cream contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. Launch Date 1984
Tinea corporis 19 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf	Curative	Approved 8583	LOTRISONE Approved Use LOTRISONE cream contains a combination of clotrimazole, an azole antifungal, and betamethasone dipropionate, a corticosteroid, and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. Launch Date 1984

C_max

Value	Dose	Co-administered	Analyte	Population
2.4 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7882513	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:		CLOTRIMAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.98 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018713_S004_MYCELEX%20TROCHE_AP.pdf	10 mg single, buccal dose: 10 mg route of administration: Buccal experiment type: SINGLE co-administered:		CLOTRIMAZOLE serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
12.59 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7882513	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:		CLOTRIMAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.99 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7882513	1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered:		CLOTRIMAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.25 h OTHER GOV'T https://www.medicines.org.uk/emc/product/11464/smpc	500 mg single, vaginal dose: 500 mg route of administration: Vaginal experiment type: SINGLE co-administered:		CLOTRIMAZOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg 5 times / day multiple, oral Recommended Dose: 10 mg, 5 times / day Route: oral Route: multiple Dose: 10 mg, 5 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	unhealthy, 33 years (range: 22 - 43 years) Health Status: unhealthy Age Group: 33 years (range: 22 - 43 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	Disc. AE: Nausea, Taste abnormality... AEs leading to discontinuation/dose reduction: Nausea (2 patients) Taste abnormality (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/2073120
500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Disc. AE: Vulvovaginal pruritus... AEs leading to discontinuation/dose reduction: Vulvovaginal pruritus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Disc. AE: Vulvovaginal burning sensation... AEs leading to discontinuation/dose reduction: Vulvovaginal burning sensation (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
50 mg 1 times / day multiple, vaginal Dose: 50 mg, 1 times / day Route: vaginal Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Disc. AE: Vaginal irritation, Spotting vaginal... AEs leading to discontinuation/dose reduction: Vaginal irritation (1 patient) Spotting vaginal (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf

AEs

AE	Significance	Dose	Population
Nausea	2 patients Disc. AE	10 mg 5 times / day multiple, oral Recommended Dose: 10 mg, 5 times / day Route: oral Route: multiple Dose: 10 mg, 5 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	unhealthy, 33 years (range: 22 - 43 years) Health Status: unhealthy Age Group: 33 years (range: 22 - 43 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2073120
Taste abnormality	2 patients Disc. AE	10 mg 5 times / day multiple, oral Recommended Dose: 10 mg, 5 times / day Route: oral Route: multiple Dose: 10 mg, 5 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2073120	unhealthy, 33 years (range: 22 - 43 years) Health Status: unhealthy Age Group: 33 years (range: 22 - 43 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2073120
Vulvovaginal pruritus	1 patient Disc. AE	500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
Vulvovaginal burning sensation	1 patient Disc. AE	500 mg single, vaginal Highest studied dose Dose: 500 mg Route: vaginal Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/4025444 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
Spotting vaginal	1 patient Disc. AE	50 mg 1 times / day multiple, vaginal Dose: 50 mg, 1 times / day Route: vaginal Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf
Vaginal irritation	1 patient Disc. AE	50 mg 1 times / day multiple, vaginal Dose: 50 mg, 1 times / day Route: vaginal Route: multiple Dose: 50 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A1 1 CYP3A2 10 CYP2C11 4 CYP2B1/2 3 CYP1A 70 CYP2E1 1060 UGT1A1 246 UGT1A3 89 UGT1A4 98 UGT1A6 136 UGT1A9 148 UGT2B7 197 UGT2B15 84 MRP1 116		CYP1A 59 P-gp 301

Drug as perpetrator

Target	Modality	Activity
CYP2E1 1146	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	no
CYP3A2 13	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.00315 uM]
CYP3A1 5	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.00822 uM]
CYP2B1/2 4	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.1 uM]
CYP2C11 15	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 0.745 uM]
CYP1A 122	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/6/837.short Page: -	yes [IC50 2.3 uM]
UGT1A1 303	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A3 99	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A4 100	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A6 171	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT1A9 155	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT2B15 84	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
UGT2B7 210	inhibitor 4027 Sources: https://www.sciencedirect.com/science/article/pii/S0163725820302199 Page: -	yes [IC50 >10 uM]
CYP1A 122	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0024320504008598 Page: -	yes
MRP1 232	inhibitor 4027 Sources: https://febs.onlinelibrary.wiley.com/doi/full/10.1046/j.0014-2956.2001.02611.x Page: -	yes
P-gp 1932	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S1096495920301329 Page: -	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.sciencedirect.com/science/article/pii/S1056871905000523 Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3764	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3764
ChemicalBook	CB7404063	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7404063
eMolecules	499093	https://www.emolecules.com/cgi-bin/more?vid=499093
MolPort	MolPort-002-557-756	https://www.molport.com/shop/molecule-link/MolPort-002-557-756
Selleck Chemicals	Clotrimazole(Canesten)	http://www.selleckchem.com/products/Clotrimazole(Canesten).html
ZINC	ZINC000003807804	http://zinc15.docking.org/substances/ZINC000003807804

PubMed

Title	Date	PubMed
[Vulvovaginal candidiasis in childhood--diagnostic and therapeutic results].	2001	11799748
Topical treatment for vaginal candidiasis (thrush) in pregnancy.	2001	11687074
A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections.	2001	11486455
Drug sensitivity of Candida yeast isolated from patients with allergic diseases.	2001 Apr	11550023
Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism.	2001 Apr 5	11334355
Application of capillary zone electrophoresis with off-line solid-phase extraction to in vitro metabolism studies of antifungals.	2001 Aug	11519954
A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.	2001 Aug	11505264
State-dependent block of rabbit vascular smooth muscle delayed rectifier and Kv1.5 channels by inhibitors of cytochrome P450-dependent enzymes.	2001 Aug	11454936
Suppression of transient outward potassium currents in mouse ventricular myocytes by imidazole antimycotics and by glybenclamide.	2001 Aug	11454921
Regulation of anion secretion by nitric oxide in human airway epithelial cells.	2001 Aug	11435220
Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1.	2001 Aug 24	11425865
Inhibition and stimulation of phospholipid scrambling activity. Consequences for lipid asymmetry, echinocytosis, and microvesiculation of erythrocytes.	2001 Aug 7	11478914
Effects of clotrimazole on transport mediated by multidrug resistance associated protein 1 (MRP1) in human erythrocytes and tumour cells.	2001 Dec	11737211
Regulation of K(+) current in human airway epithelial cells by exogenous and autocrine adenosine.	2001 Dec	11698258
Toward a novel metal-based chemotherapy against tropical diseases. 6. Synthesis and characterization of new copper(II) and gold(I) clotrimazole and ketoconazole complexes and evaluation of their activity against Trypanosoma cruzi.	2001 Dec 31	11754267
A novel drug-regulated gene expression system based on the nuclear receptor constitutive androstane receptor (CAR).	2001 Feb	11405283
Therapeutic strategies for prevention of sickle cell dehydration.	2001 Jan-Feb	11358364
Development of a mucoadhesive dosage form for vaginal administration.	2001 Jul	11548861
In vitro metabolism of 14C-moxidectin by hepatic microsomes from various species.	2001 Jul	11469506
Evaluation of two self-care treatments for prevention of vaginal candidiasis in women with HIV.	2001 Jul-Aug	11486720
[Therapeutic efficacy of a topical tolnaftate preparation in guinea pig model of tinea pedis].	2001 Jun	11521512
An investigation into the pathogenesis of vulvo-vaginal candidosis.	2001 Jun	11402224
A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion.	2001 Jun	11375331
Clotrimazole is a selective and potent inhibitor of rat cytochrome P450 3A subfamily-related testosterone metabolism.	2001 Jun	11353752
Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis.	2001 Jun 15	11377375
In vitro activity of sertaconazole, fluconazole, ketoconazole, fenticonazole, clotrimazole and itraconazole against pathogenic vaginal yeast isolates.	2001 Mar	11484411
Comparison of in vitro activities of amphotericin, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum.	2001 May	11411855
What happens in cidal and static action?	2001 May	11398272
Substantivity of topically applied antifungals on dermatophytic toe webs.	2001 May	11398270
Optimization of the separation of a group of antifungals by capillary zone electrophoresis.	2001 May 11	11403486
Intracellular signalling involved in activation of the volume-sensitive K+ current in Ehrlich ascites tumour cells.	2001 Oct	11913449
[How I treat ... sickle cell anemia: current therapies].	2001 Oct	11765575
In vitro activity of 6 antifungal agents on candida species isolated as causative agents from vaginal and other clinical specimens.	2001 Oct	11744942
Novel effects of minocycline on Ca(2+)-dependent Cl(-) secretion in human airway epithelial Calu-3 cells.	2001 Oct 15	11601886
Angiotensin II type AT(2) receptor mRNA expression and renal vasodilatation are increased in renal failure.	2001 Sep	11566953
Conservation of signaling pathways of xenobiotic-sensing orphan nuclear receptors, chicken xenobiotic receptor, constitutive androstane receptor, and pregnane X receptor, from birds to humans.	2001 Sep	11518807
Use of topical clotrimazole in human keratomycosis.	2001 Sep-Oct	11528261
Activation of ion secretion via proteinase-activated receptor-2 in human colon.	2002 Feb	11804840
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3.	2002 Feb 1	11826162
Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel.	2002 Feb 1	11724775
Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity.	2002 Feb 15	11830454
Clotrimazole binds to heme and enhances heme-dependent hemolysis: proposed antimalarial mechanism of clotrimazole.	2002 Feb 8	11707446
Comparison of two methods for antifungal susceptibility testing of Trichophyton rubrum.	2002 Jan	11913509
Development of a topical suspension containing three active ingredients.	2002 Jan	11858522
Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine.	2002 Jan 1	11682233
Differential pulse polarographic determination of clotrimazole after derivatization with Procion Red HE-3B.	2002 Jan 1	11682227
Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections.	2002 Jan-Feb	11860579
K+ currents generated by NMDA receptor activation in rat hippocampal pyramidal neurons.	2002 Jun	12037201
Effect of antifungal azoles on the heme detoxification system of malarial parasite.	2002 Mar	11872173
Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.	2002 May 17	12016269

Patents

Sample Use Guides

In Vivo Use Guide

Vaginal 1% cream: insert an applicator full of cream into the vagina at bedtime for 7 days. External 1% cream for vaginal yeast infections: apply to the skin outside the vagina 2 times daily for up to 7 days. Topical 1% cream: apply a thin layer to the affected area twice daily for 2 weeks (tinea pedis) or 1 week (tinea cruris and tinea corporis).

Route of Administration: Topical

In Vitro Use Guide

In vitro antifungal activity indicated Clotrimazole (MIC 16 and 8 microg/ml) effective against 68 (70%) of Candida SPP.

Name

Type

Language

LOTRISONE COMPONENT CLOTRIMAZOLE

Preferred Name

English

CLOTRIMAZOLE

Official Name

English

CLOTRIMAZOLE [GREEN BOOK]

Common Name

English

SVT-15652

Code

English

CLOTRIMAZOLE [ORANGE BOOK]

Common Name

English

GNF-PF-3499

Code

English

CLOTRIMAZOLE [USP IMPURITY]

Common Name

English

TRIVAGIZOLE

Brand Name

English

clotrimazole [INN]

Common Name

English

CLOTRIMAZOLE [MART.]

Common Name

English

CLOTRIMAZOLE [JAN]

Common Name

English

Clotrimazole [WHO-DD]

Common Name

English

GYNIX

Brand Name

English

BAY-5097

Code

English

LOTRIMIN

Brand Name

English

CLOTRIMAZOLE [MI]

Common Name

English

GYNE-LOTRIMIN

Brand Name

English

CLOTRIMAZOLE [EP IMPURITY]

Common Name

English

BAY 5097

Code

English

1-(2-CHLOROTRITYL)IMIDAZOLE

Systematic Name

English

CLOTRIMAZOLE [USP MONOGRAPH]

Common Name

English

MYCELEX

Brand Name

English

CLOTRIMAZOLE [EP MONOGRAPH]

Common Name

English

NSC-257473

Code

English

1-(O-CHLORO-.ALPHA.,.ALPHA.-DIPHENYLBENZYL)IMIDAZOLE

Common Name

English

CLOTRIMAZOLE [VANDF]

Common Name

English

1-((2-CHLOROPHENYL)DIPHENYLMETHYL)-1H-IMIDAZOLE

Systematic Name

English

CLOTRIMAZOLE [USAN]

Common Name

English

1H-IMIDAZOLE, 1-((2-CHLOROPHENYL)DIPHENYLMETHYL)-

Systematic Name

English

CLOTRIMAZOLE [USP-RS]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 524.1044G